'Naturalistic' Trial In GSK's Nicotine Mouth Spray NDA Historic For OTC NRTs
Executive Summary
What FDA describes as "real world" trial was "designed to include a broader patient population and without providing any verbal behavioral support," says GSK. "Historically, the FDA has not required OTC NRTs to demonstrate efficacy in naturalistic conditions," it says.
You may also be interested in...
GSK’s Proposal For Mouth Spray Nicorette Delayed By FDA Questions On Label
Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.
US Health Market In 2019: Unfinished Business Leaves Lasting Impression
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
‘Late, But Not Too Late’ For OTC Industry To Join The Digital Health Revolution
Speaking during a recent webinar, IQVIA Consumer Health's Andy Tisman gave consumer health firms three pieces of sage advice to help them seize the opportunity offered by digitalization.